Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma
Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized trial showed. After 4 years of follow-up, neither the median PFS nor the 3-year PFS differed significantly among four treatment groups who received lenalidomide (Revlimid) and bortezomib (Velcade) plus dexamethasone […]
Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically recurrent prostate cancer, according to interim results from a phase III trial. In the three-arm PRESTO study, adding either apalutamide (Erleada) or apalutamide plus abiraterone acetate (Zytiga) and prednisone […]
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
MADRID — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead of switching to another androgen receptor pathway inhibitor (ARPI), a randomized trial showed. In patients with prior progression on an ARPI, median rPFS increased from 5.9 months with another ARPI […]
Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer
MADRID — Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, according to the DUO-E trial. The trial assessed the combination of durvalumab (Imfinzi) and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus the PARP inhibitor olaparib (Lynparza) or durvalumab […]
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial. Patients who received encorafenib (Braftovi) plus binimetinib (Mektovi) had a median PFS of 12.9 months as compared with 9.2 and 7.4 months for two cohorts treated with encorafenib alone. The […]
Novel IDH1/2 Inhibitor Shows ‘Dramatic Effect’ in Low-Grade Glioma
CHICAGO — Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO trial. Among 331 patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, who received no prior treatment other than surgery, those randomly assigned to receive […]
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO — Imaging-based progression-free survival (PFS) was significantly longer with the PARP inhibitor rucaparib (Rubraca) compared with physician’s choice of therapy in patients with BRCA or ATM-associated metastatic castration-resistant prostate cancer (CRPC), the phase III TRITON3 study showed. All patients in the study had already progressed after treatment with a second-generation androgen receptor-pathway inhibitor […]
Adding Targeted Drug to Chemo Boosts Survival in Esophageal/GEJ Cancer
SAN FRANCISCO — Adding a Claudin (CLDN) inhibitor to chemotherapy significantly increased progression-free (PFS) and overall survival (OS) in locally advanced gastric/gastroesophageal junction (GEJ) cancer and CLDN 18.2 expression, a randomized trial showed. Median PFS increased from 8.67 months with modified FOLFOX chemotherapy to 10.61 months with the addition of investigational zolbetuximab. Median OS improved […]
Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer
NEW YORK — An immunotherapy-chemoradiotherapy (CRT) combination did not boost progression-free survival (PFS) in untreated, locally advanced cervical cancer, according to CALLA trial findings. Newly diagnosed patients who received durvalumab (Imfinzi) plus standard CRT did not experience a statistically significant PFS improvement versus patients who received placebo plus CRT (hazard ratio 0.84, 95% CI 0.65-1.08, […]
‘Potential New Standard’ for Progressing Desmoid Tumors
PARIS — Progression-free survival (PFS) was significantly prolonged in patients with progressing desmoid tumors treated with an investigational gamma secretase inhibitor in a phase III trial. In the international DeFi study of more than 140 patients, risk for disease progression or death was reduced by 71% in the group randomized to nirogacestat, with a median […]